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Abstract
Circulating vitamin B6 levels have been found to be inversely associated with lung cancer. Most
studies have focused on the B6 form pyridoxal 5′-phosphate (PLP), a direct biomarker influenced
by inflammation and other factors. Using a functional B6 marker allows further investigation of
the potential role of vitamin B6 status in the pathogenesis of lung cancer. We prospectively
evaluated the association of the functional marker of vitamin B6 status, the 3-
hydroxykynurenine:xanthurenic acid ratio (HK:XA), with risk of lung cancer in a nested case-
control study consisting of 5,364 matched case control pairs from the Lung Cancer Cohort
Consortium (LC3). We used conditional logistic regression to evaluate the association between
HK:XA and lung cancer, and random effect models to combine results from different cohorts and
regions. High levels of HK:XA, indicating impaired functional B6 status, were associated with an
increased risk of lung cancer, the odds ratio comparing the fourth and the first quartiles (OR 4th vs
1st) was 1.25 [95% confidence interval, 1.10-1.41]. Stratified analyses indicated that this
association was primarily driven by cases diagnosed with squamous cell carcinoma. Notably, the
risk associated with HK:XA was approximately 50% higher in groups with a high relative
frequency of squamous cell carcinoma, i.e. men, former and current smokers. This risk of
squamous cell carcinoma was present in both men and women regardless of smoking status.
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Introduction
Lung cancer is the most common cause of cancer related death, contributing to almost 20%
of all cancer deaths worldwide1. The four major histological types of lung cancer are
adenocarcinomas, squamous cell carcinomas, large cell carcinomas, and small cell
carcinomas. The most important risk factor for lung cancer is smoking, but the strength of
the association depends on the type of lung cancer2. Some lung cancer types like small cell
and squamous cell carcinomas occur almost exclusively due to smoking, while others, like
adenocarcinomas, also occur frequently in non-smokers2.
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Vitamin B6 may play a role in carcinogenesis, since it is involved in DNA synthesis,
methylation, and repair3, chromosomal stability4 and oxidative stress5. Indeed, circulating
B6 measured as pyridoxal 5′-phosphate (PLP) was found to be inversely associated with
lung cancer risk in two earlier case control studies, nested in prospective cohorts67, but in a
recent analysis within the Lung Cancer Cohort Consortium (LC3), vitamin B6 was found to
be only marginally associated with cancer risk in former and current smoking men8.
However, circulating levels of the vitamin B6 measure used in these papers, the widely used
PLP, are influenced by factors other than vitamin B6 status. These factors include
inflammation, alkaline phosphatase activity, low serum albumin and renal function9, and
reduce the usefulness of PLP as a marker of vitamin B6 status.
A recently established functional marker of vitamin B6 status is the ratio of circulating
levels of two metabolites in the kynurenine pathway of tryptophan metabolism, 3-
hydroxykynurenine (HK) and xanthurenic acid (XA), i.e. HK:XA [4]. The conversion of HK
to XA is catalyzed by the PLP-dependent enzyme kynurenine aminotransferase, while the
formation of HK does not require PLP10. The substrate-product ratio HK:XA has been
shown to increase in B6 deficient individuals and reduced to normal levels after
supplementation with B610.
Given the drawbacks of PLP as a marker of vitamin B6 status, the aim of the present study
was to use the functional vitamin B6 marker HK:XA to further investigate the role of
vitamin B6 status as a predictor of lung cancer risk. The study used data from over 5,000
cases-controls pairs from the Lung Cancer Cohort Consortium (LC3), nested within 20
prospective cohorts from the USA, Europe, Asia and Australia.
Methods
Study population
All prospective cohort studies within the National Cancer Institute (NCI) Cancer
Consortium were invited to participate in the study. Twenty cohorts, from USA (11 cohorts),
Europe (total of 4 cohorts from Norway, Sweden, and Finland), Asia (4 cohorts consisting of
Chinese populations residing in Shanghai and Singapore) and Australia (1 cohort), fulfilled
the inclusion criteria (having cryopreserved baseline plasma or serum samples, and being
members of the US National Cancer Institute (NCI) Cohort Consortium in 2009) and
accepted to participate. Details on design of the cohorts and their follow-up procedures have
been previously published8.
Selection of cases and controls
Lung cancer cases were defined on the basis of the International Classification of Diseases
for Oncology, Second Edition (ICD-O-2) and included invasive cancers coded as C34.0-
C34-9. From the 11,399 incident lung cancer cases with pre-diagnostic blood samples, 5,545
cases were selected by oversampling never and former smoking cases. For each case, one
control was randomly chosen from risk-sets consisting of all cohort members alive and free
of cancer (except non-melanoma skin cancer) at the time of diagnosis of the index case.
Matching criteria were cohort, sex, date of blood collection, and date of birth. Controls were
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also matched by smoking status at time of blood collection in 5 categories; never smokers,
short and long term quitters among former smokers (<10 years, ≥10 years since quitting),
and light and heavy smokers among current smokers (< 15, ≥15 cigarettes per day). In total,
5,364 lung cancer case-control pairs were eligible for inclusion after excluding cases who
were not correctly matched on smoking status (n=124), who had insufficient plasma sample
volume for analysis of biomarkers (n=42), or had a revised date of diagnosis prior to blood
draw (n=13)8.
Biochemical analyses
Analysis of all serum or plasma samples was performed in the Bevital A/S laboratory (http://
www.bevital.no) in Bergen, Norway. Concentrations of HK, XA, PLP and cotinine, a
marker of recent nicotine exposure11 were determined using a liquid chromatography–
tandem MS assay12, and C-reactive protein (CRP) was analysed by immuno-MALDI-MS13
in batches of 86 samples. Quality control procedures included 6 calibration plasma, 2 control
plasma, and 1 blank sample (water) in each batch. All blood samples were stored at −80°C
or lower until analysis and cases and their matched controls were analyzed together within
the same batches in random order, with laboratory staff blinded to case-control status.
Further details on the biochemical analyses have been published elsewere8.
Statistical analysis
We used conditional logistic regression (conditioning on individual case sets) to calculate
the odds ratios (OR) with 95% confidence intervals (CI) for lung cancer according to levels
of HK:XA. The analysis was adjusted for smoking intensity using quartiles of cotinine
concentrations based on the distribution of cotinine among current smokers. We performed
analyses within each cohort, comparing the fourth to the first quartile (OR 4th vs 1st) of
HK:XA. Results were combined for each region (United States [USA], Europe, Asia,
Australia), and for the overall study population by using random effects models.
Heterogeneity across subgroups was quantitatively assessed by the Q-test and I2 index14.
We further performed stratified analyses for sex, smoking category (never, former, and
current smokers), histology of lung cancer (by HK:XA tertiles), and time between blood
sample collection and diagnosis. Due to the large differences in vitamin status between
regions15, quartiles (or tertiles) of concentrations for each biomarker were based on the
distribution among controls by region. We additionally used conditional logistic regression
for calculating the odds ratio for lung cancer across quartiles by region and for the total
population, using the first quartile as reference. Quartiles were included as a continuous
variable to calculate p for trend.
In supplementary analysis stratified by histology in addition to smoking status or sex we
included HK:XA as a continuous variable, using the base-2 logarithm (log2) of the
biomarker in a conditional logistic regression model. Estimates from this model may be
interpreted as the relative risk associated with a doubling in circulating biomarker
concentration. Partial Spearman correlations adjusted for age and sex were used to describe
the association between HK:XA and PLP, and both biomarkers with cotinine. All statistical
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analyses were conducted using R 3.2.2 for Macintosh16. The package “survival”17 was used
for conditional logistic regression, and package “metafor” for forestplots18.
Results
Study population
The final study population included 5,364 lung cancer cases and 5,364 matched controls,
with a median age of 62 years at blood sample collection (Table 1). Median time between
blood draw and lung cancer diagnosis was 6.3 years. Of the total study population, 46% of
the participants were women. At baseline, nearly half of the participants were current
smokers, and one fourth were former, and never smokers, respectively (Table 1). Due to
different inclusion criteria in the original cohorts, five cohorts (Health Professionals Follow-
up Study, Physicians Health Study, ATBC, The Shanghai Cohort Study and The Shanghai
Mens’ Health Study) included only men, and five cohorts (WHI, NYUWHS, WHS, NHS
and SWHS) only women (Figure 1). The prevalence of smoking also differed substaintially
between cohorts (Figure 1).
Determinants of HK:XA within the LC3
HK:XA varied somewhat across regions, (median values ranging from 2.88 to 3.28 among
controls) with the lowest level among Australian controls and the highest among Europeans.
Larger variations were observed for plasma PLP, with the highest concentrations in the
controls from US cohorts (median 49.9 nmol/L) and the lowest concentrations among the
European cases, at 28.1 nmol/L. We observed an inverse relation between HK:XA and PLP
(Spearman rho =−0.37), while smoking was essentially not associated with HK:XA (rho
=0.11), but was inversely related to plasma PLP (rho =−0.30) (all p<0.001).
HK:XA and lung cancer
Random effects models were used to investigate the relation of HK:XA with risk of lung
cancer across geographic regions because the heterogeneity by cohort varied significantly
across the geographic regions (Supplemental Table S1). Overall, high levels of HK:XA (4th
vs. 1st quartile) were associated with a 25% increased risk for lung cancer (Figure 2).
However, results differed across regions with positive associations observed in Europe, with
an odds ratio comparing the fourth and the first quartiles (95% confidence interval) of 1.43
(1.06, 1.95), and the USA 1.31 (1.05, 1.62), but no association in Asia or Australia (Figure
2). Results were similar when using quartiles based on the distribution of each region,
instead of cohort specific cut-offs (Supplemental Table S2).
The weakest associations were observed in cohorts that included only women. When those
cohorts (The Women’s Health Intiative, The New York University Women’s Health Study,
Women’s Health Study and Nurses Health Study) were excluded, the association of HK:XA
with risk of lung cancer in the USA was similar, 1.41 (1.15, 1.46), to that seen in Europe.
Additional adjustment for CRP, a marker for systemic inflammation, did not attenuate the
risk association for HK:XA (data not shown).
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Analyses stratified by sex and smoking
In analysis stratified by sex the overall association between HK:XA and lung cancer risk
was primarily seen among men, with a 50% increased risk of lung cancer when comparing
fourth vs. first quartile (Figure 3). No significant association was observed for women, (p
heterogeneity = 0.01 and I2 = 62.4%, Supplemental Table S3). Smoking habits differed
between sexes, with the proportion of never smokers much higher among women (Figure 1).
A similar effect modification was present for smoking categories, with the association
between HK:XA and lung cancer limited to current and former smokers (p for heterogeneity
=0.18, I2 = 30.1%, Supplemental Table S4) (Figure 4).
Histology of lung cancer
Histology of lung cancer differed according to smoking status, with squamous cell
carcinoma being more common among current and former smokers (28% and 20%
respectively, compared to 6% among never smokers) and in men compared to women (29%
vs. 10%). In analysis according to histology of lung cancer in the overall population,
HK:XA was related to an increased risk for squamous cell carcinoma OR (95%CI) 1.42
(1.10, 1.82) for 3rd vs. 1st tertile, but not with other histological types (data not shown).
This association with HK:XA and squamous cell carcinoma was consistently present in
subgroup analysis by both sex and smoking status. Specifically, for a continuous log2
model, representing a doubling of HK:XA concentrations, the OR (95%CI) was 1.20 (1.02,
1.41) in men, 1.59 (1.20, 2.10) in women (Supplemental Figure S2). In current smokers the
OR (95% CI) was 1.22 (1.02, 1.46), in former smokers 1.37 (1.08, 1.73), and in never
smokers 1.59 (0.90, 2.80), even though in this last group the confidence interval was quite
wide due to the low number of cases (Supplemental figure S1).
Time to diagnosis
In analysis stratified by time to diagnosis, the association was limited to participants who
were diagnosed with lung cancer within 36 months from blood draw, ORlog2 (95%CI) 1.43
(1.27, 1.61) for a doubling in the concentration of HK:XA. No significant association
between HK:XA and lung cancer risk was observed for those with a longer time between
blood draw and diagnosis (p for heterogeneity <0.001).
Discussion
Main findings
High levels of HK:XA, indicating an impaired functional vitamin B6 status, were associated
with an increased risk of lung cancer. In stratified analysis the risk of lung cancer was
approximately 50% higher for those in the highest category of HK:XA in men, and in
former and current smokers, but not significant in women or never smokers. In analysis
stratified by histology HK:XA was associated with an increased risk of squamous cell
carcinoma, but not other histological types. When histopathology subtype of lung cancer
was considered, a consistent association was found for squamous cell carcinoma regardless
sex and smoking status. The lack of association of HK:XA with overall lung cancer among
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women and never smokers could be at least partly attributed to the low number of cases of
squamous cell carcinoma in those strata of the present study population.
Comparison with previous findings
Overall, our findings are in agreement with published results on the B6 vitamer PLP and
cancer risk19, even though stronger inverse associations were noted in relation to lung
cancer in the EPIC6 and ATBC7 studies. Concordant with the current study, we recently
observed an inverse association of PLP with lung cancer risk in LC3, an association that was
primarily confined to former and current smoking men8.
We observed a positive association between HK:XA and risk of squamous cell carcinoma,
but no significant association with other histological types of lung cancer. This observation
is also in line with a previous observation of an inverse association between plasma PLP and
risk of cancer primarily classified as squamous cell carcinoma8.
In EPIC an inverse association of PLP on lung cancer was also observed in never smokers,
but the number of cases that were never smokers was low (n=96)6, and this results should be
viewed with caution.
In a previous cohort study where PLP and HK:XA were simultaneously assessed as
predictors of cancer no clear association was found for any of the two markers. However,
this study had limited statistical power due to the small number of cases (ncases=85)20.
HK:XA as a marker of vitamin B6 status and predictor of lung cancer
There are consistent reports on plasma PLP as a predictor of cancer in the lungs6, 7 and other
organs19. Plasma PLP is the most commonly used marker of vitamin B6 status, but plasma
PLP concentrations are reduced by several factors linked to lung cancer carcinogenesis or
progression, such as smoking21, inflammation measured as CRP22-24, and increased level of
alkaline phosphatase25. On the other hand, inflammation and elevated alkaline phosphatase
(ALP) are not associated with impaired vitamin B6 availability in tissues9.
Smoking is associated with lower levels of PLP, and vitamin B6 status gradually improves
over years after smoking cessation26. In contrast, smoking shows no or a weak association
with the HK:XA ratio10, an observation confirmed in the present study. In the current study,
cases and controls were matched for smoking status and we additionally adjusted for
smoking intensity, using circulating cotinine concentrations. We cannot exclude residual
confounding by smoking, but since the association between HK:XA and lung cancer was
also present in former smokers, confounding by smoking is unlikely.
CRP is inversely associated with plasma PLP27, 28 but shows a weak positive association
with HK:XA10. After additional adjustment for CRP, the risk estimates of HK:XA and lung
cancer remained essentially the same, suggesting no or minor confounding from
inflammation. Elevated ALP may reduce PLP through conversion to pyridoxal (PL)9, but
HK and XA are not substrates for ALP, and one would not expect any direct effects from
ALP on the plasma levels of these metabolites.
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Similarly to the findings on PLP in the LC3 study8, the association between HK:XA and
lung cancer was stronger among participants with a short time between blood draw and
diagnoses.
Therefore, it is possible that the observed association between HK:XA and risk may reflect
impaired vitamin B6 status due to pre-clinical changes in lung cancer.
Strengths and limitations of the study
The present study is based on a an unprecedented sample of 5,364 pre-diagnostic blood
samples from lung cancer cases with comparable control samples recruited in 20 prospective
cohorts from around the world. The prospective study design minimizes the risk of reverse
causality and selection bias. The use of a centralized laboratory with a stringent quality
control protocols and cases and matched controls analyzed together minimizes any technical
differential bias, and an overrepresentation of never and former smokers provided adequate
power for stratified analysis. By using a functional marker that is largely independent on
factors that are related to circulating PLP, we found a clear inverse relation of vitamin B6
status with risk of lung cancer.
There was only one blood sample available for measurement of biomarkers for each
participant, so the association between HK:XA and lung cancer may be attenuated due to
regression dilution bias. It is possible that depending on the time of the blood draw and the
length of study follow-up, the single measurement may not represent the exposure period
most relevant for lung cancer development. Lastly, information on the histology of lung
cancer was missing for 34 % of the participants.
Conclusions
Our findings provide evidence for an inverse association of functional vitamin B6 status and
risk of lung cancer, especially squamous cell carcinoma. This expands our understanding
beyond what can be concluded from the modest relation observed for the direct vitamin B6
marker PLP8, circulating levels of which is influenced by factors other than vitamin B6
status, in this same study. It is recommended that future studies strive for a sample size large
enough to provide the power necessary for analysis stratified by duration of follow-up,
smoking and histology given the potential differences of the role of vitamin B6 in
pathogenesis and progression of different histological cancer types.
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Novelty and Impact
Low vitamin B6 status, assessed by circulating pyridoxal 5′-phosphate (PLP), has been
associated with increased risk of lung cancer. However, factors other than vitamin B6
status may contribute to lower PLP, possibly confounding its association with lung
cancer. In the present study we demonstrated, by using a novel functional biomarker of
B6 status that impaired functional vitamin B6 status was associated with increased risk of
lung cancer, especially squamous cell carcinoma.
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Figure 1.
Panel A. Distribution of smoking status stratified by sex in the different regions.Panel B.
Distribution of smoking status and sex in the different cohorts.ATBC, The Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study; CLUE, The Campaign Against Cancer
and Stroke (CLUE I) and the Campaign Against Cancer and Heart Disease (CLUE II); CPS-
II, The American Cancer Society Cancer Prevention Study-II Nutrition Cohort; HPFS,
Health Professionals Follow-up Study; HUNT, The Nord-Trøndelag Health Study; MCCS,
The Melbourne Collaborative Cohort Study; MDCS, The Malmö Diet and Cancer Study;
MEC, The Multiethnic Cohort; NHS, The Nurses’ Health Study; NSHDS, The Northern
Sweden Health and Disease Study Cohort; NYUWHS, The New York University Women’s
Health Study; PHS, Physicians’ Health Study; PLCO, Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial; SCCS, The Southern Community Cohort Study; SCHS,
The Singapore Chinese Health Study; SCS, The Shanghai Cohort Study; SMHS, The
Shanghai Men’s Health Study; SWHS, The Shanghai Women’s Health Study; WHI, The
Women’s Health Initiative; WHS, Women’s Health Study.
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Figure 2.
Forestplot showing odds ratios for lung cancer comparing the fourth to the first quartile of
HK:XAConditional logistic regression was performed for each cohort and was adjusted for
smoking intensity using quartiles of cotinine among current smokers. Cases and controls
were matched on age, sex, and smoking status. Results were combined using random effect
models for each region and in all studies combined. HK:XA, 3-
hydroxykynurenine:xanthurenic acid.
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Figure 3.
Forestplot showing odds ratios for lung cancer comparing the fourth to the first quartile of
HK:XA in the different regions, stratified by gender. Conditional logistic regression was
performed for each region and was adjusted for smoking intensity using quartiles of cotinine
among current smokers. Cases and controls were matched on age, sex, and smoking status.
Results were combined using random effect models. HK:XA, 3-
hydroxykynurenine:xanthurenic acid.
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Figure 4.
Forestplot showing odds ratios for lung cancer comparing the fourth to the first quartile of
HK:XA in the different regions, stratified by smoking status. Conditional logistic regression
was performed for each subgroup and among current smokers (adjusted for smoking
intensity using quartiles of cotinine among current smokers). Cases and controls were
matched for age, sex, and smoking status. Results were combined using random effect
models. HK:XA, 3-hydroxykynurenine:xanthurenic acid.
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